|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
VOLUME RATE OF CHANGE
Trading: SELL @ $1.8
Signal Strength: MEDIUM
Mesoblast (ASX:MSB) currently has negative rate of change of -58%. This means the current volume is less than the price 14 days ago and therefore losing momentum.
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to detect the speed of movement & give an early signal for a potential movement. By understanding the rate at which the price is moving in respect to the stocks historical trades, enables positions to be set in place based on changes in the speed of movement
Volume Rate of Change Volume (VROC) is an oscillator applied to volume rather than price and is calculated in the same manner as the Rate of Change (Price) indicator. VROC highlights increases in volume which normally occur at most significant market tops bottoms and breakouts.
Calculation: Volume Rate of Change (VROC):
1) ( Volume [today] - Volume [n days ago] ) / Volume [n days ago];
PROFILE: Mesoblast (MSB.AX)
Stock Exchange: ASX
Ticker Codes: | MSB.AX | ASX:MSB |
Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
|CLQ Clean Teq Holdings||0.25||4.2||1,049,067||-20||BEARISH|
|CUV Clinuvel Pharmaceuticals||31.84||4.1||229,573||-25||BEARISH|
|SXL Southern Cross Media||0.94||3.9||1,455,245||-43||BEARISH|
|PRT Prime Television||0.22||2.4||224,703||-81||BEARISH|
|MMS Mcmillan Shakespeare||16.79||2.3||355,350||-30||BEARISH|
|AGG Anglogold Ashanti||5.72||2.3||9,100||-15||BEARISH|